anti-cancer biosimilar

Bio & Pharma Korea’s pharmaceutical exports set to top $10 bn, led by ‘K-M7’ champions

South Korea’s pharmaceutical exports are on course to surpass $10 billion this year, underscoring the country’s growing clout in the glo...

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Steel POSCO to sell entire stake in Nippon Steel, ending equity ties

POSCO Holdings Inc. has decided to sell its entire stake in Nippon Steel Corp., according to industry sources on Wednesday, marking the end of their...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Bio & Pharma Samsung, Celltrion lead biosimilar market in Europe, US

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

Steel Dongkuk to file anti-dumping petition vs Chinese color steel imports

Dongkuk Coated Metal Co. and SeAh Steel Corp. are set to file an anti-dumping complaint against Chinese rivals in March as the country plans to impo...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Bio & Pharma Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea

A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...

Steel South Korea to levy 38% anti-dumping duties on Chinese steel products

South Korea plans to impose up to 38% provisional anti-dumping duties on Chinese hot-rolled steel plates starting next month, judging that those pro...

Steel Korea to probe Chinese, Japanese steel imports over anti-dumping claims

South Korea is set to launch an anti-dumping investigation into hot-rolled steel imports from China and Japan, according to government and industry ...

Bio & Pharma Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

Steel South Korea’s steel imports from China at 7-year high

South Korea’s imports of steel products from China climbed to their highest level in seven years despite a decrease in its total steel imports...

Bio & Pharma Korean drugmakers control more than half of European biosimilar market

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma Celltrion’s 4 new biosimilars win EU approval recommendation

Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...

Paper Korean paper makers to file anti-dumping complaint vs Japanese rivals

South Korean corrugated cardboard sheet makers such as Asia Paper Manufacturing Co. have decided to file an anti-dumping complaint against Japanese ...

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Bio & Pharma President of Latvia visits S.Korea's Daan Cancer Lab

Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...

Bio & Pharma Celltrion to break ground on CDMO plant in 2025: Chairman Seo

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Hanmi Pharma to move up launch of anti-obesity drug

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...

Bio & Pharma Samsung Bioepis gets EC's approval for Opuviz

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

Bio & Pharma Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca

Lunit Inc., a South Korean AI-powered cancer diagnostics company, has partnered with global biopharma giant AstraZeneca plc. to jointly enter the AI...

Bio & Pharma Volpara to supply breast cancer SW to US Defense Health Agency

Lunit, a South Korean cancer diagnostics AI company, said on Monday its US subsidiary Volpara Health secured a 10 billion won ($7.5 million) contr...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Energy Czech anti-trust body puts signing of nuclear power deal on hold

The Czech anti-trust body put a temporary block on the conclusion of a contract with Korea Hydro & Nuclear Power Co. (KHNP) for the construction...